Abstract

The tumor microenvironment (TME) is composed of a heterogeneous biological ecosystem of cellular and non-cellular elements including transformed tumor cells, endothelial cells, immune cells, activated fibroblasts or myofibroblasts, stem and progenitor cells, as well as the cytokines and matrix that they produce. The constituents of the TME stroma are multiple and varied, however cancer associated fibroblasts (CAF) and their contribution to the TME are important in tumor progression. CAF are hypothesized to arise from multiple progenitor cell types, including mesenchymal stem cells. Currently, isolation of TME stroma from patients is complicated by issues such as limited availability of biopsy material and cell stress incurred during lengthy adaptation to atmospheric oxygen (20% O2) in cell culture, limiting pre-clinical studies of patient tumor stromal interactions. Here we describe a microenvironment mimetic in vitro cell culturing system that incorporates elements of the in vivo lung environment, including lung fibroblast derived extracellular matrix and physiological hypoxia (5% O2). Using this system, we easily isolated and rapidly expanded stromal progenitors from patient lung tumor resections without complex sorting methods or growth supplements. These progenitor populations retained expression of pluripotency markers, secreted factors associated with cancer progression, and enhanced tumor cell growth and metastasis. An understanding of the biology of these progenitor cell populations in a TME-like environment may advance our ability to target these cells and limit their effects on promoting cancer metastasis.

Details

Title
Primary lung cancer samples cultured under microenvironment-mimetic conditions enrich for mesenchymal stem-like cells that promote metastasis
Author
Saforo Douglas 1 ; Omer, Linda 2 ; Smolenkov Andrei 3 ; Barve Aditya 1 ; Casson Lavona 3 ; Boyd, Nolan 4   VIAFID ORCID Logo  ; Clark, Geoffrey 5 ; Siskind, Leah 5 ; Levi, Beverly 6 

 University of Louisville, Department of Pharmacology & Toxicology, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Louisville, Department of Biochemistry & Molecular Genetics, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622); University of Louisville, Cardiovascular Innovation Institute, Louisville, USA (GRID:grid.470916.d) 
 University of Louisville, James Graham Brown Cancer Center, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Louisville, Cardiovascular Innovation Institute, Louisville, USA (GRID:grid.470916.d); University of Louisville, Department of Physiology, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Louisville, Department of Pharmacology & Toxicology, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622); University of Louisville, James Graham Brown Cancer Center, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Louisville, Department of Pharmacology & Toxicology, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622); University of Louisville, James Graham Brown Cancer Center, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622); University of Louisville, Department of Medicine, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2190460668
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.